Lankenau Medical Center campus chief of radiation oncology named to National Cancer Institute Task Force
Lankenau Medical CenterJuly 25, 2017News Releases
Albert DeNittis, MD, campus division chief of radiation oncology at Lankenau Medical Center, part of Main Line Health, has been awarded one of 16 positions within the National Cancer Institute’s (NCI) Steering Committees and Task Force program. He was nominated and selected to be on the Rectal-Anal Task Force by his colleagues in NCI’s Community Oncology Research Program (NCORP) physician/scientist community across the country. Dr. DeNittis will serve a three-year term on the Task Force, starting Sunday, October 1, 2017.
At Main Line Health, Dr. DeNittis serves as a principle investigator of NCORP, a cancer clinical trials program. Main Line Health is one of only 34 community sites in the United States—and one of only two in Pennsylvania—offering NCORP. The program provides Main Line Health patients with access to NCI-sponsored oncology clinical trials that study screening, prevention, and symptom management. Patients in the program have access to state-of-the-art clinical studies and new cancer treatments before they become available to the general public.
For the NCI Task Force, Dr. DeNittis will provide input and guidance that can help ensure the cancer clinical trials developed and approved by NCI meet the needs of surgical, medical and radiation oncologists around the country and the patients they treat.
“I am looking forward to helping the Task Force with its crucial work in setting new standards in care for patients with cancers of the rectum and anus,” said Dr. DeNittis, who also serves as a clinical professor at Lankenau Institute for Medical Research, part of Main Line Health. “In particular, I hope to help integrate NCI’s new translational and clinical research initiatives into practice at cancer care centers around the nation for the betterment of patients.”
The Rectal-Anal Task Force membership is composed of investigators from NCI-funded multi-site networks, as well as community oncologists, patient advocates and biostatisticians. According to NCI officials, the Task Force:
Develops and refines phase 3 clinical trial concepts
Advises on the scientific merit of phase 2 and phase 3 trial concepts
Advises and organizes clinical trial planning meetings
Monitors ongoing clinical research studies
In Main Line Health’s NCORP program, Dr. DeNittis is supported by more than 30 sub-investigators in medical, radiation and surgical oncology, along with clinical research nurses and coordinators at Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital. Main Line Health currently offers more than 60 cancer clinical trials across a variety of cancer types to patients across the system. Real-time trial information is available at limr.org/ncorp.
About Main Line Health
Founded in 1985, Main Line Health is a not-for-profit health system serving portions of Philadelphia and its western suburbs. Main Line Health’s commitment—to deliver advanced medicine to treat and cure disease while also playing an important role in prevention and disease management as well as training physicians and other health care providers—reflects our intent to keep our community and ourselves well ahead. A team of more than 10,000 employees and 2,000 physicians care for patients throughout the Main Line Health system.
At Main Line Health’s core are four of the region’s most respected acute care hospitals—Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital—as well as one of the nation’s recognized facilities for rehabilitative medicine, Bryn Mawr Rehabilitation Hospital.
The Main Line Health system also includes Mirmont Treatment Center for drug and alcohol recovery; Main Line Health HomeCare & Hospice, which includes skilled home health care, hospice and home infusion services; Main Line Health Centers, primary and specialty care, lab and radiology, and other outpatient services located in Broomall, Collegeville, Concordville, Exton and Newtown Square; Lankenau Institute for Medical Research, a biomedical research organization; and Main Line HealthCare, one of the region’s largest multispecialty physician networks.
Main Line Health is the recipient of numerous awards for quality care and service, including System Magnet® designation, the nation’s highest distinction for nursing excellence, the Mid-Atlantic Alliance for Performance Excellence (MAAPE) Excellence Award, and recognition as among the nation’s best employers by Forbes magazine. Main Line Health is committed to creating an environment of diversity, respect and inclusion and has proudly embraced the American Hospital Association’s #123forEquity Pledge to Act to eliminate disparities in care. We are dedicated to advancing patient-centered care, education and research to help our community stay healthy.
About Lankenau Institute for Medical Research
Lankenau Institute for Medical Research (LIMR) is a nonprofit biomedical research institute located on the campus of Lankenau Medical Center and is part of Main Line Health. Founded in 1927, LIMR’s mission is to improve human health and well-being. Faculty and staff are devoted to advancing innovative new approaches to formidable medical challenges, including cancer, cardiovascular disease, gastrointestinal disorders and autoimmune diseases, such as diabetes and arthritis. LIMR’s principal investigators conduct basic, preclinical and translational research, using their findings to explore ways to improve disease detection, diagnosis, treatment and prevention. They are committed to extending the boundaries of human health through technology transfer and training of the next generation of scientists and physicians.